US Bancorp
MIRM icon

US Bancorp’s Mirum Pharmaceuticals MIRM Stock Holding History

US Bancorp’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Buy
2,470
+1,665
+207% +$167K ﹤0.01% 1910
2026
Q1 		$74.4K Buy
805
+60
+8% +$5.64K ﹤0.01% 2531
2025
Q4 		$58.8K Sell
745
-771
-51% -$55.3K ﹤0.01% 2625
2025
Q3 		$111K Buy
1,516
+86
+6% +$5.47K ﹤0.01% 2303
2025
Q2 		$72.8K Sell
1,430
-3
-0.2% -$134 ﹤0.01% 2599
2025
Q1 		$64.6K Buy
1,433
+60
+4% +$2.83K ﹤0.01% 2615
2024
Q4 		$56.8K Buy
1,373
+196
+17% +$8.17K ﹤0.01% 2677
2024
Q3 		$45.9K Buy
1,177
+1,030
+701% +$41.1K ﹤0.01% 2782
2024
Q2 		$5.03K Sell
147
-9
-6% -$236 ﹤0.01% 3512
2024
Q1 		$3.92K Buy
156
+41
+36% +$1.13K ﹤0.01% 3584
2023
Q4 		$3.4K Buy
115
+43
+60% +$1.3K ﹤0.01% 3608
2023
Q3 		$2.27K Hold
72
– – ﹤0.01% 3632
2023
Q2 		$1.86K Hold
72
– – ﹤0.01% 3703
2023
Q1 		$1.73K Sell
72
-68
-49% -$1.55K ﹤0.01% 3789
2022
Q4 		$2.73K Buy
+140
New +$2.77K ﹤0.01% 3697

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's MIRM Position: Q2 2026 in Review

US Bancorp increased its Mirum Pharmaceuticals (MIRM) stake by 207% in Q2 2026, buying an estimated $167K and bringing the position to 2,470 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

US Bancorp first reported a position in MIRM in Q4 2022 and has held it in 15 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • US Bancorp held 2,470 shares of Mirum Pharmaceuticals worth $289K as of Q2 2026.
  • US Bancorp bought 1,665 Mirum Pharmaceuticals shares in Q2 2026, an estimated $167K.
  • Mirum Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1910 holding.
  • US Bancorp first reported a position in Mirum Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.